Immune System and Transfer Factor :Immune System and Transfer Factor


Immune System :Immune System The health of the body is dependent on the immune system's ability to recognize and then react and remember germs and cancers.


Major Lines of Immune Defense :Major Lines of Immune Defense Innate Immunity Passive Active Skin Inflammatory Cells Mucus Natural Killer Cells Stomach Acid Phagocytic Cells Tears Natural Antibodies Interferon Complement proteins Acquired Immunity Active B Cells Immune Memory cells T Cells Antibodies


Characteristics of Innate and Acquired Immunity :Characteristics of Innate and Acquired Immunity Innate Acquired Prior exposure to the Requires exposure to microbe not required microbe Nonspecific Specific Repeat exposure does Memory for re- not change response exposure Natural antibodies Elicited antibodies Complement system Cytotoxic Lymphocytes Natural Killer cells Memory B and T cells Phagocytes Plasma cells (antibodies)


The Innate Immune System :The Innate Immune System Cells (N K cells) are the 1st line defenders against cancer and infectious disease. It initiates and improves the slower but more specific acquired immune response.


In 1949 H. Sherwood Lawrence, Ph.D. was attempting to understand the immune response and how it was conveyed. :In 1949 H. Sherwood Lawrence, Ph.D. was attempting to understand the immune response and how it was conveyed.


Slide 7:+ + + + + + - - -


Response to an Infectious Threat :Response to an Infectious Threat First Exposure Primary Response Second Exposure Secondary Response Memory Cell


PRIMARY IMMUNE RESPONSE :PRIMARY IMMUNE RESPONSE


PRIMARY IMMUNE RESPONSE :PRIMARY IMMUNE RESPONSE A cut in the skin damages cells and allows bacteria into the body signaling an immune response from macrophages and other scavenger immune cells. Mast cells release chemicals that trigger inflammation, allowing other immune cells to rush to the problem area. Before reinforcements arrive, macrophages and other prestationed immune cells start attacking bacteria, chop them up into bits called antigens. They are then transported to lymph nodes where these macrophages attach to B cells and T cells. B cells begin producing antibodies specifically for the particular antigens or germs the body is exposed to. The antibodies trigger responses from certain immune cells like NK cells, macrophages and killer T cells to engulf and kill the bacteria-infected cells. Helper T cells signal the antibodies and killer T cells to go directly to the wound. While the immune cells are taking care of the germs, other cells called platelets begin healing the wound by forming clots which close the wound


SECONDARY IMMUNE RESPONSE :SECONDARY IMMUNE RESPONSE


SECONDARY IMMUNE RESPONSE :SECONDARY IMMUNE RESPONSE A cut in the skin damages cells and allows bacteria into the body signaling an immune response from macrophages and other scavenger immune cells. Mast cells release chemicals that trigger inflammation, allowing other immune cells to rush to the problem area. Before reinforcements arrive, macrophages and other pre-stationed immune cells start attacking bacteria, chop them up into bits called antigens. B cells, set in motion by previous immune responses, begin producing antibodies specifically for the particular antigens or germs the body is exposed to. The antibodies trigger responses from certain immune cells like NK cells, macrophages and killer T cells to engulf and kill the bacteria-infected cells. Helper T cells signal the antibodies and killer T cells to go directly to the wound. While the immune cells are taking care of the germs, other cells called platelets begin healing the wound by forming clots which close the wound.


Secondary Immune Response :Secondary Immune Response Transfer Factor 1. Early Recognition 2. Quick Response 3. Massive Response 4. Allows Us to Win “The Numbers Game” 5. Provides Resistance 6. Resistance Equals Immunity 7. Immunity Provides Protection 8. Key to Immunity - Memory Molecule Memory Molecule Is:


SOURCES OF TRANSFER FACTOR :SOURCES OF TRANSFER FACTOR BLOOD (1949 LAWRENCE) WHITE BLOODCELLS CALLED LYMPHOCYTES ARE REMOVED FROM BLOOD AND TRANSFER FACTORS ARE REMOVED FROM THEM. EXPENSIVE BUT EFFECTIVE. NOT PRACTICAL FOR GENERAL USE. COLOSTRUM (1989 WILSON/PADDOCK) FIRST MATERNAL MILK PRODUCED RIGHT AT AND AFTER BIRTH. PATENTED SELECTIVE FILTRATION METHOD PERFECTED IN 1989 WHICH REMOVES TRANSFER FACTORS FROM COLOSTRUM. ECONOMICAL AND EFFECTIVE. PRACTICAL FOR GENERAL USE.


Source of Transfer Factor :Source of Transfer Factor NO PESTICIDES NO ANTIBIOTICS NO HORMONES Dry ULTRA FILTRATION FILTER


From the Cow to YouTransfer Factor™ Quality :From the Cow to YouTransfer Factor™ Quality Quality Assurance and Product Safety Communications Dr. Rick Bennett


The TF Farms and Cows :The TF Farms and Cows Farms in the United States “Grade A” Dairies State and Federal quality controls Pasture and Corral fed


Colostrum Production :Colostrum Production Colostrum “milked” for the first day + Baby calves get plenty Harvested as for Grade A Milk Frozen on farm


Colostrum TF Processing :Colostrum TF Processing Frozen then thawedat plant Defatted Batch Pasteurized (LTLT) Ultra-filtered to concentrate Transfer Factor™ Low temp. sprayed dried ™


Quality Assurance: HACCP :Quality Assurance: HACCP Known hazards Documented interventions Electronic monitoring True QA !


Transfer Factor Safety Communications Key Points :Transfer Factor Safety Communications Key Points USFDA Grade A Dairies USDA and State Approved Food Processing Plants Pasteurized Colostrum and TF Ultra-filtrate (3x Microbial safety control) Antibiotics cannot be legally used in “milking” cows- Milk and colostrum routinely tested rBST not “generally” used on TF farms Mad Cow disease NOT present in US ™


Transfer Factor Quality Assured, Ready for Product Formulation and You :Transfer Factor Quality Assured, Ready for Product Formulation and You ™


IMPORTANT POINTS :IMPORTANT POINTS DAIRY CATTLE PRODUCE LARGE AMOUNTS OF COLOSTRUM-MORE THAN THE CALF NEEDS. TRANSFER FACTORS ARE THE SAME FOR ALL SPECIES. HUMAN AND COW TRANSFER FACTORS ARE MOLECULARLY IDENTICAL!!!


WHY NOT JUST COLOSTRUM? :WHY NOT JUST COLOSTRUM? COLOSTRUM WATER VITAMINS/MINERALS PROTEIN FAT CARBORHYDRATES (LACTOSE) IMMUNOGLOBULINS (SPECIES-SPECIFIC ANTIBODIES) SLIGHT GROWTH HORMONE TRANSFER FACTORS TRANSFER FACTOR™ TRANSFER FACTORS IT IS ESTIMATED TO TAKE 45 GM OF COLOSTRUM (OR 45,000 MG) TO GET THE EQUIVALENT TRANSFER FACTORS IN 600 MG OF 4LIFE™ TRANSFER FACTOR™.


CHARACTERISTICS OF TRANSFER FACTORS :CHARACTERISTICS OF TRANSFER FACTORS VERY SMALL POLYPEPTIDES (PROTEINS) MOLECULAR WEIGHT < 6000 DALTONS THE SAME FOR ALL SPECIES STABLE EVEN IN ACID ENVIRONMENT (NOT HYDROLYZED) ABSORABLE IN ALL-AGED RECIPIENTS NON-ALLERGENIC DUE TO SMALL SIZE HALF-LIFE THOUGHT TO BE < THREE WEEKS ORAL ADMINISTRATION THOUGHT TO BE MOST EFFECTIVE ROUTE NON-TOXIC REMEMBER #3 – TRANSFER FACTORS ARE THE SAME FOR ALL SPECIES!!


PROPERTIES OF TRANSFER FACTORS(3 FRACTIONS) :PROPERTIES OF TRANSFER FACTORS(3 FRACTIONS) INDUCER TRIGGERS A GENERAL STATE FRACTION OF READINESS IN THE IMMUNE SYSTEM ANTIGEN AN ARRAY OF CRITICAL TAGS SPECIFIC USED BY THE IMMUNE SYSTEM FRACTION TO IDENTIFY A HOST OF ENEMY MICROBES SUPPRESSOR DOWN-REGULATES THE IMMUNE FRACTION RESPONSE ONCE THE THREAT IS DEFEATED


Benefits of Transfer Factor :Benefits of Transfer Factor Emergence of new viruses or resurfacing of old pathogens. Successful use in viral, parasitic, fungal, malignant, neurological and autoimmune diseases. Cases of atopic dermatitis, herpes zoster ophthalmicus l600 pts, good to excellent results in viral, cancer, fungal, CFS, AIDS and autoimmune diseases with no acute or chronic toxicity. Congenital immunodeficiency, IgA, IgE Antibiotic-resistant infections Asthma Psoriasis Senility Hepatitis B The use of transfer factor in the prevention of illness and the maintenance of health is its greatest potential benefit and its safety when used chronically has been well demonstrated. Excellent safety record with no adverse side effect even when administered in extreme excess or over several years in all age groups.


TF in the Intensive Care Unit15 :TF in the Intensive Care Unit15 60 patients immuno-deficiencies, diabetic patients no time to wait for tests 1 unit of TF 3/d for 3 days oral, IM or IV improved response to conventional therapy reduced hospitalization time


TF and Severe Pediatric Infections12 :TF and Severe Pediatric Infections12 45 patients average age 4.2 yrs unresponsive to conventional therapy 43 cases reached remission improvement even in the 2 other cases in spite of congenital IgA and IgG deficiency


TF and Severe Pediatric Infections12 :TF and Severe Pediatric Infections12 45 patients average age 4.2 yrs unresponsive to conventional therapy 43 cases reached remission improvement even in the 2 other cases in spite of congenital IgA and IgG deficiency


Atopic Dermatitis with Transfer Factor or Cyclosporin A :Atopic Dermatitis with Transfer Factor or Cyclosporin A 30 patients Cellular immune deficiency Unresponsive to conventional therapy Both groups lowered eosinophils Cyclosporin A lowered CD4 (helper) TF raised CD8 (suppressor)


TRANSFER FACTOR :TRANSFER FACTOR More than 3,000 publications Clinical trials International Congress on Transfer Factor (XI)


US PATENTS :US PATENTS [54] FOOD AND THE METHOD OF EXTRACTING THE SAME FROM COLOSTRUM AND MILK [75] Inventors: Mary E. Collins; Robert A. Collins, both of Waukon, Iowa [73] Assignee: Impro Porducts, Inc., Wankson, Iowa [21] Appl. No.: 276,230 [22] Filed:Jun. 22, 1981 Related U.S. Application Data [63] Continuation-in-part of Ser. No. 154,502, May 29, 1980, abandoned. [51] Int. Cl.4............................................... 4A61K 39/00 [52] U.S. Cl. ........................................ 424/85; 426/583; 426/491 [53] Field of Search ...................426/580, 583, 41, 431, 426/491, 495, 657; 424/85, 86, 87 [56] References Cited: U.S. PATENT DOCUMENTS 3,128,230 4/1964 Helabach...................424/85 3,646,193 2/1972 Michaelson et al. ......424/85 3,911,108 10/1975 Siagla.........................424/86 3,984,539 10/1976 Khouw et al...........424/85 X 4,051,235 9/1977 Plymater ....................424/85 PATENT PURPORTED BY MATOL United States Patent [19] [11] 4,402,938 Collins et al. [45] Sep. 6, 1983 4,138,501 2/1979 Chareron et al. .......426/239 4,284,623 5/1981 Beck ......................... 424/85 OTHER PUBLICATIONS Webb, B.H., “Fundamentals of Dairy Chemistry”, The Avi Publ. Co., Inc., Westport, Conn., 1965, pp. 10 and 416. Butler, J.H., :37 The Occurrence of Immunoglobulin Fragments, Two Types of Lactoferrin and a Lac- to- Ferrin-lgG2 Complex in Bovine Colostral and Milk Whey”, Biochemists et Biophsicis Acta, 295, (1973), pp. 341-351. McDonough, F.E., et al., “Protein Concentrate from Cheese Whey by Ultrafiltration”, J. Dairy Sci., vol. 54, No. 10, Oct. 1971, pp. 1406-1409. Primary Examiner -- Robert A Yoncoakie Attorney, Agent, or Firm -- Ira Milton Jones [57] ABSTRACT This invention provides a new and useful food factor for use as a nutritional supplement for animals, which product comprises whey obtained from colostrum and milk as it comes from selected cows or other ungulates, and containing an active fraction having a molecular weight on the order of 1200 or less. 6 Claims, No Drawings [54] PROCESS FOR OBTAINING TRANSFER FACTOR FROM COLOSTRUM, TRANSFER FACTOR SO OBTAINED AND USE THEREOF [75] Inventors: Gregory B. Wilson; Gary V. Paddock, both of Mount Pleasant, S.C. [73] Assignee: Amtron, Inc., Charleston, S.C. [21] Appl. No.: 670,596 [22] Filed: Nov. 15, 1984 Related U.S. Application Data [63] Continuation-in-part of Ser. No. 554,921, Nov. 25, 1983, abandoned. [51] Int. Cl.4 ........................ A61K 39/00; A61K 39/02; A61K 39/12; C07H 15/12 [52] U.S. Cl. ......................................530/344; 530/300; 536/22; 536/23; 536/24; 536/27; 514/2; 514/7; 514/8; 424/88; 424/89; 424/92; 424/105; 435/68 [58] Field of Search....................... 424/95, 105, 88, 89, 424/92, 93; 514/2, 7, 8; 530/350, 300, 832, 833, 344, 300; 536/22, 23, 24, 27 [56] References Cited PUBLICATIONS France et al Clin Res, vol. 28 863 A 1981 “Transfer Factor from Human Colostrum and Breast Milk Lymphocytes”. Ruben et al Clin Res vol. 27(4) 1979 698 A “Cell Medicated immunity to influenza A virus and influenza B virus in human colostrum and milk.” Meggs et al Am J. Obstet Gynecol vol. 133(6) 1979, pp. 703-707 “In-vitro Stimulation of human colostral lymphocytes by cytomegalovirus”. Parmely et al J. Dairy Science vol. 60(4) 1977 pp. 4LIFE TRANSFER FACTOR PATENT United States Patent [19] [11] Patent Number: 4,816,563 Wilson et al. [45] Date of Patent: Mar. 28, 1989 655-665 “Colostral cell medicated immunity and the concept of a common secretory immune system”. Schlesinger et al Lancet vol. 2 1977 pp. 529-532 “Evidence for transmission of lymphocytes response to tuberculin by brest feeding”. Wilson et al Immunobiology of Transfer Factor 1983 Kirkpatrick, Colt et al editors p. 331. Wilson et al. Immunology Today vol. 4, p. 157. Primary Examiner -- Thomas G. Wiseman Assistant Examiner -- Robin L. Teskin Attorney, Agent, or Firm -- John P. White; John J. Santalone [57] ABSTRACT Antigen specific excreted transfer factor may be ob-tained by collecting material, e.g. colostrum or milk, secreted by the mammary gland of a suitable lactating mammal, e.g. a cow having immunity to the antigen under suitable conditions such that materials which interfere with transfer factor efficacy are removed so as to obtain transfer factor. Colostrum or milk so collected may be used directly, typically after sterilization, or may be treated to further concentrate and/or purify transfer factor. Treatment to yield colostral whey con-taining transfer factor is presently the preferred method for obtaining transfer factor for use in conferring immu-nity against diseases associated with antigens for which the transfer factor is specific. Cell-associated transfer factor specific for an antigen may also be obtained by incubation release from, or lysis of, cells obtained from the collected material. An alternative method for ob-taining transfer factor is to recover it from the mam- mary tissue of a suitable lactating mammal. The transfer factor may be used in edible compositions and in phar-maceutical or veterinary compositions and in methods for conferring immunity in a human or lower animal to a disease associated with the antigen. The transfer fac- tor may then be used to prevent or treat the disease. 28 Claims, No Drawings


IMPORTANCE OF TRANSFER FACTOR(ORIGINS OF DISEASE) :IMPORTANCE OF TRANSFER FACTOR(ORIGINS OF DISEASE) THREATS FROM OUTSIDE 1. ALLERGIES 2. INFECTIONS THREATS FROM WITHIN 1. AUTO-IMMUNE 2. CANCER


MAJORITY OF DISEASES :MAJORITY OF DISEASES 1. ALLERGIES 2. INFECTIONS 3. AUTO-IMMUNE 4. CANCER ARE IMMUNE SYSTEM DYSFUNCTIONS


IF YOUR IMMUNE SYSTEM IS: :IF YOUR IMMUNE SYSTEM IS: UNDERACHIEVING INFECTION CANCER NEED TO: STIMULATE OVERACHIEVING ALLERGIES AUTO-IMMUNE NEED TO: BALANCE


Slide 37:Transfer Factor™ is an immunomodulator meaning it is best utilized to balance the immune system response. Remember Transfer Factor™ has both INDUCER and SUPPRESSOR fractions.


Slide 38:Immune Functionality's: ENHANCER SUPPRESSOR ANTIGEN SPECIFIC TRANSFER FACTOR


TRANSFER FACTOR PLUS™ :TRANSFER FACTOR PLUS™ 2ND GENERATION FORMULATION DESIGNED BY: WILLIAM HENNEN, PH.D. DIRECTOR OF R&D 4LIFE™ RESEARCH IMMUNO-STIMULANT


TRANSFER FACTOR PLUS™ :TRANSFER FACTOR PLUS™ INGREDIENTS TRANSFER FACTOR™ CORDYCEPS 3. GLUCANS (YEAST, MAITAKE, SHIITAKE) 4. MANNANS (FROM ALOE VERA) 5. IP-6 6. THYMIC FACTORS


Lymphocytes :Lymphocytes T cells : helper T cell, cytotoxic T cells, DTH T cells B cells : pro-B cell, pre-B cell, immature B cell, mature B cell NK cells : CD56bright, CD56dim NKT cells = NK like T cells LAK cell = lymphokine activated killer cells ( T-LAK, NK-LAK) TIL cell = tumor-infiltrating lymphocytes


Pivotal role of NK cells in the immune system :Pivotal role of NK cells in the immune system NK cells NKT cells


Innate immunity vs. adaptive immunity :Innate immunity vs. adaptive immunity Innate (non-specific): - skin, monocytes/macrophage system, NK cells etc. Adaptive (specific): - humoral immunity (B cells) - cellular immunity (T cells)


Interplay of Innate and Adaptive Immunity :Interplay of Innate and Adaptive Immunity The complement system is the merging point of innate and adaptive immunity. NK cells also produce a number of cytokines (messenger molecules) that are potent regulator of T cells. Dendritic cells, like macrophages, capture foreign antigens, present them to other immune cells and trigger antibody production. They also produce cytokines in response to enveloped viruses (herpes simplex and HIV).


Slide 45:Innate immunity i.e. macrophage Mediated with little antibody Adaptive immunity i.e. antibodies produced and isotype class switching Infected cell is killed Innate Humoral CTL Cytotoxicity Th1 Th2 CD4-helper CD8-suppressor http://www.health.auckland.ac.nz/courses/Biosci357/LecturesWeb/357Lecture11.htm Suppressor


NKT cells (human) :NKT cells (human) Restricted TCR repertorie : Va24-JaQ Recognize MHC class I –like CD1 Frequency - PBL : 0.1 ~ 0.5% - Liver : 4 – 5% Cytokine production - type 1 : IFN-g, IL-2, TNF-b ? anti-cancer effect - type 2 : IL-4, IL-5, IL-10 ? prevent autoimmune disease


Natural Killer Cell (I) :Natural Killer Cell (I) 10 – 20% of lymphocytes in circulating blood Natural resistance against tumors and virus infections etc. Morphology : Large Granular Lymphocytes (LGL) Marker : CD3-CD56+CD16+/-


Killer Cells :Killer Cells They target cells that are missing the self marker that identifies a cell as one of our own. Foreign cells without self markers are attacked. Low NK cell activity: cancer, congenital or acquired immunodeficiencies, severe viral infections, autoimmune diseases, behavioral disorders, several genetic disorders, chronic illness and infections. The young, the old and the stressed are more susceptible to immunologic breakdown. This may allow tumors to grow faster. Chronic fatigue immune dysfunction syndrome (CFIDS) is associated with persistently low NK activity


Natural Killer Cell (II) :Natural Killer Cell (II) Cytolytic mechanism : spontaneously killing – Ab dependent Cellular Cytotoxicity (ADCC) Cytolytic mediatros : perforin/granzyme, Fas- ligand/Fas, TNF-a, NO Self vs. non-self : MHC class I ? negative signal


Natural Killer Cell (II) :Natural Killer Cell (II) Cytolytic mechanism : spontaneously killing – Ab dependent Cellular Cytotoxicity (ADCC) Cytolytic mediatros : perforin/granzyme, Fas- ligand/Fas, TNF-a, NO Self vs. non-self : MHC class I ? negative signal


Natural Killer Cell (III) :Natural Killer Cell (III) NK cell activation : IFN-g, IL-2, IL-12, IL-18 etc. NK-cell precursor ? IL-15 ? Mature NK cell NK cell subsets : CD56bright , CD56dim


CD56 dim NK cells :CD56 dim NK cells Majority (90%) of NK cells >95% of cells are CD16bright ? ADCC are more toxic than CD56 bright cells. produce low levels of cytokines. are more granular than CD56 bight cells. have relatively low proliferative capacity. are less responsive to IL-2 induced proliferation.


Slide 65:KIR: killer cell Ig-like receptor MHC: major histocompatibility complex CD: clusters of differention CD94: C-type-lectin-inhibitory receptor NKG2:inhibitory variants NCR: natural cytotoxicity receptors ILT: Ig-like transcripts APC: antigen-presenting cells


CD56 bright NK cells :CD56 bright NK cells 10% of NK cells have the capacity to produce abundant cytokines. express high affinity IL-2 receptor (IL-2Rabg) ? low doses of IL-2 ? proliferation, enhancement of cytotoxicity major NK-cell subset in the uterus of a pregnant woman are among the first lymphocytes to repopulate the peripheral blood following BMT. clinical interest ? very low doses of IL-2 ? expand selectively this cell in cancer and HIV patients.


CYTOKINES :CYTOKINES IFN: Interferon TNF: tumor necrosis factor IL: interleukin TGF: transforming growth factors CSF: hematopoietic colony-stimulating factors


NK cells in disease :NK cells in disease Cancer, Tuberculosis - reduced NK cytotoxicity AIDS - low concentration of NK cells - reduced NK cytotoxicity Alzheimer’s disease - increased NK cytotoxicity


NK cells and immunotherapy :NK cells and immunotherapy Tumor therapy Adv. - activated NK cells are readily available for cancer therapy. - expand rapidly in culture without prior sensitization. Immunotherapy/chemotherapy Immunotherapy/genetherapy


NK cells vs. ethanol :NK cells vs. ethanol Diminished activation of NK cell lytic function - decreased production of and response to IFN-alpha - decreased levels of granzyme B and perforin


NK cells vs. aging :NK cells vs. aging Impaired NK cytotoxicity - decreased proliferative response to IL-2 the expansion of a mature NK cells Stress: NK cytotoxicity is suppressed.


NK cells vs. training :NK cells vs. training Increased the percentage of NK cells - increased NK cell activity in the group on the carbohydrate-rich diet - decreased NK cell activity in the group on the fat-rich diet


JANA STUDY* – WINTER 1999 *DARRYL M. SEE, M.D., UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA :JANA STUDY* – WINTER 1999 *DARRYL M. SEE, M.D., UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA 196 PRODUCTS STUDIED WITH OVER 400 INGREDIENTS STUDY WAS DESIGNED TO MEASURE NATURAL KILLER CELL ACTIVITY NK CELLS ARE OUR FIRST LINE OF DEFENSE


JANA TEST RESULTS :JANA TEST RESULTS PRODUCT NONI ALOE VERA ENDOCRINE FORMULA PHYTONUTRIENT FORMULA BOVINE COLOSTRUM CORDYCEPS SHIITAKE ECHINACEA (19% USE) PLANT SUGARS FORMULA IP-6 TRANSFER FACTOR™ TRANSFER FACTOR PLUS™ % RISE OVER BASELINE 1. 15% 2. 15% 3. 16% 4. 21% 5. 23% 6. 28% 7. 42% 8. 43% 9. 48% 10. 49% 11. 103% 12. 248%


TRANSFER FACTOR PLUS ADVANCED FORMULA :TRANSFER FACTOR PLUS ADVANCED FORMULA 438% Increase in NK cell activity!!!


Slide 80:In a historic move, the Ministry of Health and Social Development of the Russian Federation has given approval to a dietary supplement for use in comprehensive health care practice to 4Life. The approval opens the way for the use of these immune modulators in Russian hospitals.


Slide 81:Start prognosis: Patients had 3.7 months to live. Results after six months: 16 out of the 20 patients studied are in remission, either improving or in stable condition. Conducted by Dr. Darryl See On Stage 4 cancer patients


Slide 82:"There is no other product in a nutritional substance, nor a drug, that has this kind of power and ability to affect our immune system. With the increase of killer viruses, mutated germs, super-resistant germs, and food contaminations, our only hope and defense, must lie within our own immune system." -- Darryl See, MD Associate Clinical Professor WHO ( World Health Organization) Western Europe, Dr. See received his degree from the University of California, Irvine. Academic appointments include: Assistant/Associate Clinical Professor of Medicine: Investigator, California Collaborative Treatment Group: and Infectious Disease Consultant, Liver Transplantation Service. He has received contracts, grants, and research awards from Pfizer Pharmaceuticals, Upjohn Pharmaceuticals, Roche Molecular Systems, Harvard Biotechnology, National Institutes of Health, Department of Defense, and more….


Slide 83:TRANSFER FACTOR PLUS™ SEEKING STIMULATION INFECTION CANCER PREVENTION TRANSFER FACTOR™ SEEKING BALANCE ALLERGIES AUTO-IMMUNE DISEASES SEEKING DOWN-REGULATION


COMMONALITY HUMAN/BOVINE PATHOGENS :COMMONALITY HUMAN/BOVINE PATHOGENS HUMAN PATHOGEN OR DISEASE BOVINE PATHOGEN BACTERIA BACTERIA TRAVELERS DIARRHEA (E. COLI) VERY TOXIGENIC E. COLI VERY CAMPYLOBACTER JEJUNI BLOODY DIARRHEA/HEMOLYTIC INCREASING E. COLI O157:H7 VEROTOXIC UREMIA SALMONELLOSIS & TYPHOID FEVER COMMON SALMONELLA THYPHIMURIUM, SALMONELLA TYPHOSA DUBLIN DIARRHEA, FROM FOOD AND WATER VERY CAMPYLOBACTER JEJUNI CAUSING GUILLANE BARRE SYN. LEPTOSPIROSIS (KIDNEY FAILURE) RARE LEPTOSPIRA (MANY SEROVARS) UNDULANT FEVER RARE BRUCELLA ABORTUS (BRUCELLA ABORTUS) CLOSTRIDIAL INFECTION COMMON CLOSTRIDIA (MANY SPECIES) (NON TETANUS) C. DIFFICILE MYCOBACTERIUM INFECTIONS MYCOBACTERIUM SPECIES AVIUM RARE BOVIS RARE TUBERCULOSIS VERY JOHNEI, CROHN’S DISEASE COMMON (MOST COMMON IN JERSEY CATTLE)


COMMONALITY CONTINUED :COMMONALITY CONTINUED HUMAN PATHOGEN OR DISEASE (CONT.) BOVINE PATHOGEN (CONT.) BACTERIA (CONT.) BACTERIA (CONT.) STAPHYLOCOCCAL SUPER INFECTIONS COMMON STAPH. AUREUS STREPTOCOCCAL INFECTIONS COMMON STREPTOCOCCUS ENDOCARDITIS COMMON BETA STREPTOCOCCUS SUPERINFECTION INCREASING S. PYOGENES S. PYOGENES INCREASING ENTEROCOCCI COMMON ENTEROCOCCI (MOST SPECIES & VRE) HOSPITAL AND VRE STRAINS LISTERIOSIS AND ABORTION RARE LISTERIA MONOCYTOGENES NEONATAL MENINGEOENCEPHALITIS RARE HELIOBACTER PYLORI (ULCERS) COMMON BOVINE AND PORCINE ASSOCIATION VIRUSES VIRUSES INFLUENZA COMMON INFLUENZA VIRUS PNEUMONIA (RESP. SYNCYTIAL VIRUS) COMMON BOVINE RESP. SYNCYTIAL VIRUS PAPILLOMA, CONDYLOMAYA COMMON BOVINE PAPILLOMA VIRUS VIRUS DIARRHEA COMMON BOVINE VIRUS DIARRHEA ROTAVIRUS ROTAVIRUS CORONAVIRUS


COMMONALITY CONTINUED :COMMONALITY CONTINUED HUMAN PATHOGEN OR DISEASE (CONT.) BOVINE PATHOGEN (CONT.) VIRUSES (CONT.) VIRUSES (CONT.) CYTOMEGALOVIRUS COMMON BOVINE CMV AND IBR HERPES INFECTIONS COMMON INFECTIOUS BOVINE RHINOTRACHEITIS HIV (RETROVIRUS) COMMON BOVINE IMMUNE DEFICIENCY VIRUS LENTIVIRUS (LOW PREVALENCE) VENEZUELEAN EQUINE ENCEPHALITIS RARE BOVINE VEE LYMPHOSARCOMA RARE BOVINE ONCOVIRUS LYMPHOSARC. PSUEDOCOWPOX RARE BOVINE PARAPOXVIRUS RHINOVIRUS (COMMON COLD) VERY COMMON BOVINE RHINOVIRUS YEAST, FUNGI, PROTOZOA, OTHER MICROBES ASPERGILLOSIS RARE ASPERGILLUS EXPOSURE COMMON CANDIDIASIS COMMON CANDIDA EXPOSURE COMMON CYCLOSPORA RARE ABORTIONS? CRYPTOSPORIDIOSIS VERY COMMON CALF DIARRHEA, C. PARVUM GIARDIASIS COMMON CALF DIARRHEA, G. LAMBLIA CHLAMYDIOSES COMMON CHLAMYDIAL ABORTION MYCOPLASMA PNEUMONIA, ARTHRITIS COMMON BOVINE MYCOPLASMAL PNEUMONIA *APPLIED LIFE SCIENCES, R.H. BENNETT, PH.D., PRESIDENT, 8300 STARR ROAD, WINDSOR, CA 95492


The Future of Medicine :The Future of Medicine Will focus on the Immune System


Slide 88:Lets talk about heart disease


Slide 89:“A new test could save the lives of millions who don’t even know they’re in danger” – US News & World Report


Slide 90:TRADITIONAL RISK FACTORS that can’t be changed: 1. Heredity 2. Gender 3. Increasing Age


Slide 91:TRADITIONAL RISK FACTORS that can be changed: 1. Smoking 2. Cholesterol 3. Hypertension 4. Physical Inactivity 5. Obesity 6. Stress 7. Substance Abuse


Slide 92:IMPORTANT NEWLY RECOGNIZED risk factors: 1. Homocysteine Levels 2. C-Reactive Protein Levels


Slide 93:Homocysteine: A Cardiovascular Risk Factor Worth Considering


American Heart Disease Statistics :American Heart Disease Statistics


Strokes :Strokes 600,000 per year 160,000 deaths per year A stroke every 53 seconds 1 death every 3.3 minutes 4.5 million stroke survivors today


LAPD 4 year period death rate comparison :LAPD 4 year period death rate comparison Heart Disease—160 Gun shots—5


Medical Science’s Solution to Heart Disease :Medical Science’s Solution to Heart Disease Drugs Surgery Why does incidence remain the same?


Slide 104:Cross-section of normal coronary artery


Slide 105:Old theory of cholesterol plaque formation


Slide 106:Old theory of cholesterol plaque formation


Slide 107:Old theory of cholesterol plaque formation


Slide 110:Severe atherosclerosis with narrowing plaque formation, and hemorrhage


Effects of Elevated Homocysteine :Effects of Elevated Homocysteine Damages inside lining of artery. Damage causes increased permeability (leakage). Germs and Bad Cholesterol (LDL) leak into arterial wall. Homocysteine oxidizes LDL Cholesterol. Oxidized LDL Cholesterol more dangerous form.


Effects of Elevated Homocysteine :Germ-seeking Macrophages enter arterial wall. Macrophages get diverted. Start ingesting “tasty” oxidized LDL Cholesterol. Macrophages fill themselves with LDL Cholesterol. Look like they are filled with foam. These “foam cells” are what constitute plaques. Plaques cause ATHEROSCLEROSIS. Effects of Elevated Homocysteine


Slide 113:While commercial labs state that “normal” homocysteine levels can range from 5 to 15 umol/L, a study published in Circulation Nov. 15th, 1995 indicated that each 3 unit increase in homocysteine equals a 35% increase in cardiac risk.


Slide 115:“All the patients were tested for antibodies – a sign of past infection – to several bacteria and viruses, including herpes simplex virus 1 and 2, cytomegalovirus, Epstein-Barr virus, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae and Helicobacter pylori.”


C-Reactive Protein :C-Reactive Protein C-Reactive Protein is a protein in the body whose level increases when there is inflammation. A study published in the New England Journal of Medicine involving 1086 apparently healthy men over an eight year period showed that those men with the highest level of C-Reactive Protein had a three-fold increase in the risk of heart attack and a two-fold increase in the risk of stroke.


Cardiovascular Evaluation :Cardiovascular Evaluation Homocysteine Lipid profile (cholesterol) C-Reactive Protein (CRP)


Homocysteine :Homocysteine Folic Acid B6 B12


Cholesterol :Cholesterol Red rice yeast Significantly reduces: Total Cholesterol LDL (Bad) Cholesterol Triglycerides -Am J Clin Nutr 1999 Garlic


Inflammation (CRP) :Inflammation (CRP) Targeted Transfer Factor Red Rice Yeast Antioxidants ™


TF Cardio™ The Most Effective Cardiovascular Supplement Ever! :Block Oxidative Damage Selenium, Copper/Zinc, Resveratrol Beta carotene, Vitamin C, Vitamin E Balances Normal Blood Pressure Ranges Copper, Magnesium Improve Toxin Clearance Folic Acid, Vitamins B6 & B12, and Niacin Increase the Pumping Efficiency of the Heart Magnesium, CoQ10 Relax the Blood Vessels Arginine, Mg, Ginkgo biloba, Hawthorne, Butcher’s Broom TF Cardio™ The Most Effective Cardiovascular Supplement Ever!


French Paradox Lower incidence of Heart Disease :French Paradox Lower incidence of Heart Disease Powerful Antioxidant Reduces Blood Clotting Increases HDL cholesterol (good cholesterol) Bhat KPL, Kosmeder JW, 2nd. Antioxid Redox Signal 2001; 2(6): 1041-64. Resveratrol


SUMMARY of the Problem :SUMMARY of the Problem Heart Disease is the #1 Killer Heart Disease is NOT a Simple Plumbing Problem The Immune System is Critically Involved in Heart Disease Infection may Initiate Heart Disease Increased Homocysteine Levels add risk Elevated C-Reactive Protein Levels add risk


SUMMARY of a Solution :SUMMARY of a Solution Immune System “Targeting” to Fight Germs “Suppress” (Control) Inflammation Help the Blood Vessels Relax Protect the Heart and Arteries from Toxin and Oxidative Damage Increase the Pumping Efficiency of the Heart Decrease Homocysteine levels Decrease Cholesterol levels Decrease C-Reactive Protein levels


Health Supplement Timeline :Health Supplement Timeline 1970’s 1980’s 1990’s 2000’s Multivitamins Herbs Antioxidants Immune Support


“The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who knows the great enthusiasms, the great devotions, and spends himself in a worthy cause; who at best, if he wins, knows the thrills of high achievement, and, if he fails, at least fails daring greatly, so that his place shall never be with those cold and timid souls who know neither victory nor defeat.” :“The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who knows the great enthusiasms, the great devotions, and spends himself in a worthy cause; who at best, if he wins, knows the thrills of high achievement, and, if he fails, at least fails daring greatly, so that his place shall never be with those cold and timid souls who know neither victory nor defeat.” –Theodore Roosevelt